Astragaloside IV disrupts cancer progression through reducing fibrosis by upregulating pSmad3C, pNrf2, HO-1, and NQO1 and downregulating pSmad2C, pSmad2L, pSmad3L, PAI-1, and α-SMA. The gene discussed is NQO1; the disease is cancer.